Ergoteles’s Vertex Pharmaceuticals VRTX Stock Holding History

Ergoteles’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,145	Closed	-$3.2M	–	1559
2023 Q1	$3.2M	Buy	10,145 +3,522	+53%	+$1.06M	0.13%	150
2022 Q4	$1.91M	Buy	+6,623	New	+$2.02M	0.07%	292
2021 Q3	–	Sell	-41,211	Closed	-$8.31M	–	1710
2021 Q2	$8.31M	Buy	+41,211	New	+$8.62M	0.19%	152
2021 Q1	–	Sell	-3,961	Closed	-$936K	–	1079
2020 Q4	$936K	Buy	+3,961	New	+$909K	0.03%	343

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's VRTX Position: Q2 2023 in Review

Ergoteles sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 10,145 shares — an estimated $3.2M sold.

Ergoteles first reported a position in VRTX in Q4 2020 and held it in 4 quarters. The position peaked at $8.31M in Q2 2021. 1,285 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

Ergoteles reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 10,145 Vertex Pharmaceuticals shares in Q2 2023, an estimated $3.2M.
Ergoteles first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 4 quarters.
Ergoteles's Vertex Pharmaceuticals position peaked at $8.31M in Q2 2021.
1,285 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.